Description
Indication & Scope
Ifosfamide is an inactive prodrug activated in the liver. Active metabolites crosslink DNA strands to block tumour cell replication and induce cell death.
- Mechanism
Alkylating agent (Oxazaphosphorine) - Drug class
Injectable systemic cytotoxic chemotherapy agent - Clinical use
Oxazaphosphorine alkylating agent; requires hepatic metabolic activation. It forms DNA crosslinks to inhibit tumour cell proliferation, applied for single-agent or combined chemotherapy for multiple solid tumours and lymphoma.
| Generic Name | Ifosfamide For Injection |
| Brand Name | Pifuping® |
| Ingredient | Ifosfamide |
| Dosage Form | Injection |
| Package | 1g/vial/box |
| Conditions Treated | Treatment of testicular cancer, ovarian cancer, breast cancer, sarcoma, malignant lymphoma and lung cancer. |
| Taboos | Patients hypersensitive to ifosfamide; severe myelosuppression; pregnant and breastfeeding women. |
| Place of origin | China |
| Priscription Type | Prescription Drug |
| Storage Conditions | Sealed, store below 30°C, protected from light |
| Manufacturer | Jiangsu Hengrui Medicine Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | H10950292 |
| Approval Date | July 29, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Reconstitute and dilute for intravenous infusion, dosage calculated according to body surface area. Mesna must be co-administered to prevent urotoxicity.
Time: Intravenous infusion, typically administered for consecutive 5 days per treatment cycle; repeat every 3–4 weeks.
Instructions for use: For intravenous infusion only; concomitant mesna and adequate hydration are mandatory to avoid bladder injury. Monitor complete blood count, renal and hepatic function regularly during therapy. Effective contraception is required for patients of childbearing age.
Interaction: Combination with other myelosuppressive chemotherapy increases haematological toxicity risk. Concurrent nephrotoxic agents may aggravate renal injury. Live vaccines are contraindicated.
Side effects: Myelosuppression, nausea, vomiting, alopecia, haemorrhagic cystitis.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
Must mesna be given together with Pifuping®?
Yes. Mesna should be administered to prevent urotoxicity and haemorrhagic cystitis.
Which patients cannot receive Pifuping®?
Patients with hypersensitivity, severe myelosuppression, pregnancy or lactation are prohibited.
What routine monitoring is required during treatment?
Regular monitoring of blood routine, renal function and liver function is essential.
Can live vaccines be administered during chemotherapy?
Live vaccines are not allowed during treatment.
Pifuping® | Ifosfamide For Injection | Cancer And Tumour | DengYueRX
INN: Ifosfamide
Indications: Cancer And Tumour
Dosage Form: Injection
Strength: 1g/Vial
Original price was: $18.62.$15.82Current price is: $15.82.
